Efficacy and complications of cavo-tricuspid isthmus-dependent atrial flutter ablation in patients with and without structural heart disease: results from the German Ablation Registry.


Journal

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 23 12 2019
accepted: 04 05 2020
pubmed: 28 5 2020
medline: 19 8 2021
entrez: 28 5 2020
Statut: ppublish

Résumé

The impact of structural heart disease (SHD) on safety and efficacy of catheter ablation of cavo-tricuspid isthmus-dependent atrial flutter (AFLU) is unclear. In addition, recent data suggest a higher complication rate of AFLU ablation compared to the more complex atrial fibrillation (AF) ablation procedure. Within our prospective multicenter registry, 3526 consecutive patients underwent AFLU ablation at 49 German electrophysiological centers from 2007 to 2010. For the present analysis, the patients were divided into a group with SHD (n = 2164 [61.4%]; median age 69 years; 78.5% male) and a group without SHD (n = 1362 [38.6%]; 65 years; 70.3% male). In our study, SHD mainly encompasses coronary artery disease (52.6%), left ventricular ejection fraction ≤ 50% (47.6%), and hypertensive heart disease (28.0%). The primary ablation success (97%) and the incidence of major (0.2%) or moderate (1.2%) complications did not differ significantly between the two groups (P = 1.0 and 0.87, respectively). Vascular access site complications (0.6%), AV block III° (0.2%), and bleeding (≥ BARC II: 0.2%) were most common. After a median 562 days of follow-up, we observed a 2.92-fold higher one-year mortality (P < 0.0001) in patients with SHD. Patients' satisfaction with the ablation therapy (72.0% satisfied) was close to the overall subjective tachyarrhythmia-free rate (70.7%). The present analysis demonstrates that ablation of cavo-tricuspid isthmus dependent AFLU in patients with SHD has a comparable, excellent risk-benefit profile in our large "real-world" registry. Mortality rates expectedly are higher in patients with SHD and AFLU compared to patients without SHD. CLINICALTRIALS.GOV: NCT01197638, http://clinicaltrials.gov/ct2/show/NCT01197638.

Sections du résumé

BACKGROUND BACKGROUND
The impact of structural heart disease (SHD) on safety and efficacy of catheter ablation of cavo-tricuspid isthmus-dependent atrial flutter (AFLU) is unclear. In addition, recent data suggest a higher complication rate of AFLU ablation compared to the more complex atrial fibrillation (AF) ablation procedure.
METHODS AND RESULTS RESULTS
Within our prospective multicenter registry, 3526 consecutive patients underwent AFLU ablation at 49 German electrophysiological centers from 2007 to 2010. For the present analysis, the patients were divided into a group with SHD (n = 2164 [61.4%]; median age 69 years; 78.5% male) and a group without SHD (n = 1362 [38.6%]; 65 years; 70.3% male). In our study, SHD mainly encompasses coronary artery disease (52.6%), left ventricular ejection fraction ≤ 50% (47.6%), and hypertensive heart disease (28.0%). The primary ablation success (97%) and the incidence of major (0.2%) or moderate (1.2%) complications did not differ significantly between the two groups (P = 1.0 and 0.87, respectively). Vascular access site complications (0.6%), AV block III° (0.2%), and bleeding (≥ BARC II: 0.2%) were most common. After a median 562 days of follow-up, we observed a 2.92-fold higher one-year mortality (P < 0.0001) in patients with SHD. Patients' satisfaction with the ablation therapy (72.0% satisfied) was close to the overall subjective tachyarrhythmia-free rate (70.7%).
CONCLUSIONS CONCLUSIONS
The present analysis demonstrates that ablation of cavo-tricuspid isthmus dependent AFLU in patients with SHD has a comparable, excellent risk-benefit profile in our large "real-world" registry. Mortality rates expectedly are higher in patients with SHD and AFLU compared to patients without SHD. CLINICALTRIALS.GOV: NCT01197638, http://clinicaltrials.gov/ct2/show/NCT01197638.

Identifiants

pubmed: 32458180
doi: 10.1007/s10840-020-00769-z
pii: 10.1007/s10840-020-00769-z
doi:

Banques de données

ClinicalTrials.gov
['NCT01197638']

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

55-62

Références

Perez FJ, Schubert CM, Parvez B, Pathak V, Ellenbogen KA, Wood MA. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. Circ Arrhythm Electrophysiol. 2009;2:393–401.
doi: 10.1161/CIRCEP.109.871665
Eckardt L, Frommeyer G, Sommer P, Steven D, Deneke T, Estner HL, et al. Updated survey on interventional electrophysiology: 5-year follow-up of infrastructure, procedures, and training positions in Germany. JACC Clin Electrophysiol. 2018;4:820–7.
doi: 10.1016/j.jacep.2018.01.001
Inama G, Pedrinazzi C, Adragao P, Alvarez M, Arribas F, Bonhorst D, et al. Five years of catheter ablation procedures in South-Western Europe: meta-analysis of National Registries. Pacing Clin Electrophysiol. 2009;32:506–15.
doi: 10.1111/j.1540-8159.2009.02312.x
Kesek M. Ablation procedures in Sweden during 2007: results from the Swedish Catheter Ablation Registry. Europace. 2009;11:152–4.
doi: 10.1093/europace/eun298
Steinbeck G, Sinner MF, Lutz M, Muller-Nurasyid M, Kaab S, Reinecke H. Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014. Eur Heart J. 2018;39:4020–9.
doi: 10.1093/eurheartj/ehy452
Brachmann J, Lewalter T, Kuck KH, Andresen D, Willems S, Spitzer SG, et al. Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German Ablation Registry. Eur Heart J. 2017;38:1317–26.
doi: 10.1093/eurheartj/ehx101
Calkins H, Canby R, Weiss R, Taylor G, Wells P, Chinitz L, et al. Results of catheter ablation of typical atrial flutter. Am J Cardiol. 2004;94:437–42.
doi: 10.1016/j.amjcard.2004.04.058
Da Costa A, Faure E, Thevenin J, Messier M, Bernard S, Abdel K, et al. Effect of isthmus anatomy and ablation catheter on radiofrequency catheter ablation of the cavotricuspid isthmus. Circulation. 2004;110:1030–5.
doi: 10.1161/01.CIR.0000139845.40818.75
Lewalter T, Weiss C, Spencker S, Jung W, Haverkamp W, Willems S, et al. Gold vs. platinum-iridium tip catheter for cavotricuspid isthmus ablation: the AURUM 8 study. Europace. 2011;13:102–8.
doi: 10.1093/europace/euq339
Schmieder S, Ndrepepa G, Dong J, Zrenner B, Schreieck J, Schneider MA, et al. Acute and long-term results of radiofrequency ablation of common atrial flutter and the influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. Eur Heart J. 2003;24:956–62.
doi: 10.1016/S0195-668X(02)00846-1
Gilligan DM, Zakaib JS, Fuller I, Shepard RK, Dan D, Wood MA, et al. Long-term outcome of patients after successful radiofrequency ablation for typical atrial flutter. Pacing Clin Electrophysiol. 2003;26:53–8.
doi: 10.1046/j.1460-9592.2003.00150.x
Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess. 2008;12:iii-iv, xi-xiii, 1–198.
doi: 10.3310/hta12340

Auteurs

Dirk G Dechering (DG)

Department of Cardiology II, Electrophysiology, University Hospital Muenster, Albert-Schweitzer Campus 1, D-48159, Münster, Germany. dirk.dechering@ukmuenster.de.

Bernd-Dieter Gonska (BD)

Innere Medizin mit Schwerpunkt Kardiologie, Angiologie und Intensivmedizin, St. Vincentius-Kliniken gAG, Karlsruhe, Germany.

Johannes Brachmann (J)

Department of Cardiology, Angiology, and Pneumology, Second Medical Clinic, Coburg Hospital, Coburg, Germany.

Thorsten Lewalter (T)

Isar Heart Center, Munich, Germany.

Karl-Heinz Kuck (KH)

Department of Cardiology, Asklepios Klinik St Georg, Hamburg, Germany.

Dietrich Andresen (D)

Department of Cardiology and Internal Medicine, Vivantes Klinikum Am Urban, Berlin, Germany.

Stephan Willems (S)

Department of Electrophysiology, University Heart Center Hamburg, Hamburg, Germany.

Stefan G Spitzer (SG)

Praxisklinik Herz und Gefaesse, Dresden, Germany.

Florian Straube (F)

Heart Center Munich-Bogenhausen, Munich Municipal Hospitals, Munich, Germany.

Burghard Schumacher (B)

Westpfalz-Klinikum GmbH, Kaiserslautern, Germany.

Matthias Hochadel (M)

Institute for Research in Myocardial Infarction, Ludwigshafen, Germany.

Jochen Senges (J)

Institute for Research in Myocardial Infarction, Ludwigshafen, Germany.

Lars Eckardt (L)

Department of Cardiology II, Electrophysiology, University Hospital Muenster, Albert-Schweitzer Campus 1, D-48159, Münster, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH